Title: Autologous Stem Cell Transplantation (AuSCT) for Multiple Myeloma (MM) (CAG-00444R2)

Decision: The Centers for Medicare & Medicaid Services (CMS) has reconsidered one aspect of the existing National Coverage Determination (NCD) for Stem Cell Transplantation (110.23). Specifically, CMS is expanding coverage for single Autologous Stem Cell Transplantation (AuSCT) for certain beneficiaries with multiple myeloma (MM) who have active disease as defined by the International Myeloma Working Group, as well as to include any stage of MM using the International Staging System (ISS) clinical tool and its revisions. Coverage of all other indications for stem cell transplantation not otherwise specified in the NCD will continue to be made by local Medicare Administrative Contractors (MACs).

What this means: Coverage for single AuSCT for MM was previously limited to patients within Stage II (intermediate cell mass) or Stage III (high cell mass) using the Durie-Salmon Staging System who fit certain requirements. Single AuSCT for MM will now be covered for individuals who meet the criteria outlined in section B.II.b of revised NCD 110.23, including patients who have active disease and who are either in any stage of MM using the ISS tool or within Stages II or III of the Durie-Salmon Staging System. Coverage of all other indications for stem cell transplantation not otherwise specified in the NCD may be covered for members subject to any requirements that may be established by the local MACs and/or HealthPartners. Please refer to the final decision memo for all coverage criteria.

Effective: October 28, 2026

This announcement can be found at: Decision Memo for Autologous Stem Cell Transplantation (AuSCT) for Multiple Myeloma (MM)

HealthPartners is a health plan that contracts with both Medicare and the Minnesota Medical Assistance (Medicaid) program to provide benefits of both programs to enrollees. HealthPartners is also a Cost plan and PPO plan with a Medicare contract. Enrollment in HealthPartners depends on contract renewal.

H2422_90242 IR Approved 07/2015
Y0095_90242 IR Approved 01/2026